Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Kylie Jenner displays her VERY edgy fashion sense in cleavage
Kylie Jenner put her edgy eye for style on display once again as she stepped out in the Los Angeles2024-05-22Wicked stepmother accused of torturing 12
A Pennsylvania woman accused of torturing her stepdaughter to death served years in prison after her2024-05-22Greene pitches 7 sharp innings, Reds beat Diamondbacks 6
PHOENIX (AP) — Hunter Greene pitched seven effective innings, Will Benson hit a two-run homer and th2024-05-22- Gunmen killed a five-year-old boy in a hail of bullets - after the child ran out to greet his father2024-05-22
Student fatally shot, suspect detained at Georgia's Kennesaw State University
ATLANTA (AP) — Officials at Georgia’s Kennesaw State University say a student was killed in a weeken2024-05-22China to initiate issuance of ultra
BEIJING, May 13 (Xinhua) -- China will issue ultra-long special treasury bonds starting Friday to ra2024-05-22
atest comment